Bernd Schmidt
Director Técnico/Científico/I+D en SENSORION .
Perfil
Bernd Schmidt is currently the Chief Technical Officer at Sensorion SA since 2023.
Prior to this, he worked as the Vice President-Product Delivery at Quell Therapeutics Ltd.
Mr. Schmidt is a graduate of Friedrich-Alexander University of Erlangen-Nuremberg.
Cargos activos de Bernd Schmidt
| Empresas | Cargo | Inicio |
|---|---|---|
| SENSORION | Director Técnico/Científico/I+D | 11/12/2023 |
Antiguos cargos conocidos de Bernd Schmidt.
| Empresas | Cargo | Fin |
|---|---|---|
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formación de Bernd Schmidt.
| Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SENSORION | Health Technology |
| Empresas privadas | 1 |
|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Bernd Schmidt
